Sheba Medical Center

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Media Advisory: Surescripts’ Data & Analytics Chief Nowak to Speak at ViVE 2024 on Digital Technology, AI and Advancing Health Intelligence Sharing

Retrieved on: 
Wednesday, February 21, 2024

Surescripts® Chief Data and Analytics Officer Lynne Nowak, M.D., will share insights as part of a panel at ViVE 2024 , Navigating Digital Transformation and AI in Healthcare, on February 26, 2024, at 2:40 p.m. PT.

Key Points: 
  • Surescripts® Chief Data and Analytics Officer Lynne Nowak, M.D., will share insights as part of a panel at ViVE 2024 , Navigating Digital Transformation and AI in Healthcare, on February 26, 2024, at 2:40 p.m. PT.
  • My kids will even tell you about the two-foot-tall stacks of paper charts and hours at home writing out forms,” said Nowak.
  • Panelists: Lynne Nowak, MD, Chief Data & Analytics Officer, Surescripts, Bill Fera, MD, Principal/Healthcare AI Leader, Deloitte, and Eyal Zimlichman, MD, Chief Transformation Officer & Chief Innovation Officer, Sheba Medical Center.
  • Explore how digital tools, including AI, are revolutionizing care delivery and can alleviate burnout, improve patient outcomes, and streamline operational processes.

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
Wednesday, January 31, 2024

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

SAMARITAN'S PURSE AIRLIFTS LIFE-SAVING TRAUMA SUPPLIES TO ISRAEL

Retrieved on: 
Friday, January 12, 2024

BOONE, N.C., Jan. 12, 2024 /PRNewswire/ -- Tomorrow, Samaritan's Purse will airlift 1,000 Advanced Trauma Life Support kits to Israel on its 757 cargo plane.

Key Points: 
  • BOONE, N.C., Jan. 12, 2024 /PRNewswire/ -- Tomorrow, Samaritan's Purse will airlift 1,000 Advanced Trauma Life Support kits to Israel on its 757 cargo plane.
  • War is horrific, and innocent civilians are suffering," said Franklin Graham, president of Samaritan's Purse.
  • "Samaritan's Purse is committed to helping families in need, and we are grateful to be able to support Magen David Adom with ambulances and these life-saving trauma kits.
  • To date, Samaritan's Purse has provided 18,500 food boxes, nearly 4,000 hot meals, and more than 18,000 food vouchers to families in need.

TytoCareS Giveback Program Expands with New Kesem Partnership

Retrieved on: 
Thursday, November 9, 2023

In its latest TytoCareS partnership, TytoCare has formed a new partnership with Kesem, a children’s nonprofit organization, all aimed at expanding access to primary care.

Key Points: 
  • In its latest TytoCareS partnership, TytoCare has formed a new partnership with Kesem, a children’s nonprofit organization, all aimed at expanding access to primary care.
  • The company is announcing a partnership with Kesem through the TytoCareS giveback program.
  • The TytoCareS giveback program is another layer in TytoCare’s mission to provide unparalleled access to care for families across the world.
  • “We could not be more thrilled about the partnership with Kesem and TytoCare,” said Alexandra Baldwin, VP of Operations at Kesem.

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Retrieved on: 
Tuesday, November 7, 2023

“We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.

Key Points: 
  • “We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.
  • She has had a distinguished career as a practicing physician, biopharmaceutical industry executive and sector investor,” said Jacob Harel, PolyPid’s Chairman.
  • I would also like to thank Anat for her distinguished service and counsel as a member of PolyPid’s Board since April 2008.
  • In her most recent role at Sanofi, she served as Global Established Products Medical Lead – Strategic Decision for Portfolio Enhancement.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Virology Education Presents the Demystifying Long COVID-19 International Conference 2023 7-9 December 2023

Retrieved on: 
Thursday, October 19, 2023

Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.

Key Points: 
  • Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.
  • This new initiative provides a global platform for this vital cross-disciplinary discussion.
  • What do we know about the global prevalence, risk factors, and long-term evolution of long COVID?
  • How to improve the care pathways in the light of what is organized in different countries?

Clinical Study Conducted at Medical University of South Carolina Finds Synchrony Medical's LibAirty™ Airway Clearance System Highly Effective for Chronic Lung Disease Patients

Retrieved on: 
Wednesday, October 18, 2023

CHARLESTON, S.C. and OR YEHUDA, Israel, Oct. 18, 2023 /PRNewswire/ -- The results of a clinical study of Synchrony Medical's LibAirty™ Airway Clearance System showed that the system was twice as effective in clearing mucus from the lungs of patients with chronic lung disease when compared to the standard of care therapy. The findings were announced in an oral presentation at CHEST2023 in Honolulu, Hawaii.

Key Points: 
  • The study, led by Dr. Patrick A. Flume at the Medical University of South Carolina (MUSC), randomized patients to receive two treatments: LibAirty™ and the standard of care in random order.
  • The system was effective and well tolerated by all subjects, which suggests its potential to enhance clinical outcomes in airway clearance for patients with chronic respiratory disease," said Dr. Flume.
  • "Synchrony's vision is to improve respiratory therapy for patients living with chronic lung disease by bringing best practice respiratory therapy to their homes.
  • Daily airway clearance is essential for millions of patients living with chronic lung disease to prevent respiratory infections and costly hospitalizations.

Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors

Retrieved on: 
Wednesday, October 11, 2023

LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.

Key Points: 
  • LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.
  • Beyond this board position, Mr. Miller will also take on an advisory role, contributing to the company's strategy and business development efforts.
  • Renovaro Biosciences has recently signed a definitive agreement to combine with GEDiCube, a UK-based medical AI company specializing in early detection and remissions of cancer, and expedited drug discovery ( Renovaro Press Release ) ( GEDiCube press release ).
  • I am delighted to have the opportunity to assist the company as a board member and an advisor working closely with the company’s leadership team,” said Avram Miller.